Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY03003 sustained-release rotigotine microspheres in early primary Parkinson's disease
ChiCTR1900027183Phase 3Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Rotigotine extended-release microspheres in Parkinson's disease (PD) (2 arms), sponsored by Xuanwu Hospital. Primary endpoint: Change in UPDRS total score (Parts II + III) from baseline to end of double-blind dose maintenance period. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
Rotigotine extended-release microspheres
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR1900027183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900027183.